{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:53:21Z","timestamp":1781880801093,"version":"3.54.5"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Antinuclear antibody\u2010positive multiple sclerosis (<jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>) patients have shorter disease duration and lower Expanded Disability Status Scale (<jats:styled-content style=\"fixed-case\">EDSS<\/jats:styled-content>) scores. The aim of this study was to compare clinical and laboratory features between <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content> and neuromyelitis optica (<jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content>) patients with and without autoantibodies and to investigate the prognosis of <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> in patients with and without autoantibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The frequencies of antinuclear, anti\u2010Sj\u00f6gren's syndrome A (<jats:styled-content style=\"fixed-case\">SSA<\/jats:styled-content>)\/Ro, anti\u2010Sj\u00f6gren's syndrome B (<jats:styled-content style=\"fixed-case\">SSB<\/jats:styled-content>)\/La and anti\u2010thyroid peroxidase (<jats:styled-content style=\"fixed-case\">TPO<\/jats:styled-content>) antibodies in the sera of 75 <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> patients and 131 <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content> patients were compared. Clinical and laboratory profiles were also compared between <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> patients with and without autoantibodies, including annual relapse rate and time from onset of <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> to <jats:styled-content style=\"fixed-case\">EDSS<\/jats:styled-content> scores of 4.0 (limited walking but without aid) and 6.0 (walking with unilateral aid).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>More <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> than <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content> patients had antinuclear and anti\u2010<jats:styled-content style=\"fixed-case\">SSA<\/jats:styled-content>\/Ro antibodies (31% vs. 10%, <jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.001, and 21% vs. 3%, <jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.001, respectively). Antinuclear antibody\u2010positive <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> patients had a lower annual relapse rate from disease onset to serum sampling compared with antinuclear antibody\u2010negative <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> patients, independent of treatment regimen. Antinuclear antibody\u2010negative <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> patients reached an <jats:styled-content style=\"fixed-case\">EDSS<\/jats:styled-content> score of 6.0 earlier than antinuclear antibody\u2010positive <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> patients (<jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.026). Cerebrospinal fluid cell counts were higher in anti\u2010<jats:styled-content style=\"fixed-case\">SSA<\/jats:styled-content>\/Ro\u2010positive than in anti\u2010<jats:styled-content style=\"fixed-case\">SSA<\/jats:styled-content>\/Ro\u2010negative <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> patients. More anti\u2010<jats:styled-content style=\"fixed-case\">TPO<\/jats:styled-content> antibody\u2010positive than anti\u2010<jats:styled-content style=\"fixed-case\">TPO<\/jats:styled-content> antibody\u2010negative <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content> patients had oligoclonal immunoglobulin G bands (60% vs. 11%, <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.048).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Autoantibodies possibly modulate the pathophysiology of <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content>. Antinuclear antibody may be associated with less severe disease activity or less disability in <jats:styled-content style=\"fixed-case\">NMO<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.12714","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T09:27:31Z","timestamp":1429694851000},"page":"276-281","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica"],"prefix":"10.1111","volume":"23","author":[{"given":"H.","family":"Masuda","sequence":"first","affiliation":[{"name":"Department of Neurology Graduate School of Medicine Chiba University Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Neurology Graduate School of Medicine Chiba University Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Uzawa","sequence":"additional","affiliation":[{"name":"Department of Neurology Graduate School of Medicine Chiba University Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Muto","sequence":"additional","affiliation":[{"name":"Department of Neurology Graduate School of Medicine Chiba University Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Neurology Graduate School of Medicine Chiba University Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Department of Neurology Graduate School of Medicine Chiba University Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2007.17"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511431077"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311427550"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.02.008"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.03.009"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-004-0338-x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_6_11_1","unstructured":"Japan Thyroid Association website.http:\/\/www.japanthyroid.jp\/doctor\/guideline\/english.html#basedou(accessed 11\/01\/2014)."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp309"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2011.190"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2007.04.008"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/135245859900500209"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1982.00510200046008"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90575-9"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fene.12714","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.12714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:47:34Z","timestamp":1695570454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.12714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,22]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/ene.12714"],"URL":"https:\/\/doi.org\/10.1111\/ene.12714","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,22]]},"assertion":[{"value":"2014-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}